- Home
- IPA vs SABS Comparison
IPA vs SABS Comparison
Compare IPA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- SABS
- Stock Information
- Founded
- IPA 1983
- SABS 2014
- Country
- IPA Canada
- SABS United States
- Employees
- IPA N/A
- SABS N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- SABS Health Care
- Exchange
- IPA Nasdaq
- SABS Nasdaq
- Market Cap
- IPA 19.3M
- SABS 19.0M
- IPO Year
- IPA 2017
- SABS N/A
- Fundamental
- Price
- IPA $0.39
- SABS $1.82
- Analyst Decision
- IPA Strong Buy
- SABS Strong Buy
- Analyst Count
- IPA 2
- SABS 5
- Target Price
- IPA $5.00
- SABS $12.40
- AVG Volume (30 Days)
- IPA 1.3M
- SABS 246.2K
- Earning Date
- IPA 03-13-2025
- SABS 03-28-2025
- Dividend Yield
- IPA N/A
- SABS N/A
- EPS Growth
- IPA N/A
- SABS N/A
- EPS
- IPA N/A
- SABS N/A
- Revenue
- IPA $17,272,336.00
- SABS $1,512,723.00
- Revenue This Year
- IPA $1.88
- SABS N/A
- Revenue Next Year
- IPA $9.90
- SABS N/A
- P/E Ratio
- IPA N/A
- SABS N/A
- Revenue Growth
- IPA 6.36
- SABS N/A
- 52 Week Low
- IPA $0.33
- SABS $1.60
- 52 Week High
- IPA $2.43
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- IPA 36.66
- SABS 36.28
- Support Level
- IPA $0.43
- SABS $2.00
- Resistance Level
- IPA $0.53
- SABS $2.15
- Average True Range (ATR)
- IPA 0.04
- SABS 0.20
- MACD
- IPA -0.01
- SABS 0.03
- Stochastic Oscillator
- IPA 8.42
- SABS 30.99
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.